• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Imaging and Intervention

Prophylactic LMWH not associated with prevention of VTE after arthroscopy or casting: The POT-KAST and POT-CAST trials

byDavid ArsaniousandShaidah Deghan, MSc. MD
February 9, 2017
in Imaging and Intervention, Surgery
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Prophylactic low-molecular-weight heparin (LMWH) for 8 days post knee arthroscopy demonstrated no change in the incidence of venous thromboembolism (VTE) or major bleeding events compared to placebo.

2. Prophylactic LMWH during the full period of immobilization due to casting of the lower extremity demonstrated no change in the incidence of VTE or major bleeding events compared to placebo.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Arthroscopic knee surgery is the most commonly performed orthopedic procedure worldwide. While it has been established that knee arthroscopy, and also casting of the lower leg, increase patients’ risk for VTE, it is uncertain whether pharmacologic thromboprophylaxis after these procedures is an effective means of risk reduction. The Prevention of Thrombosis after Knee Arthroscopy (POT-KAST) and the Prevention of Thrombosis after Lower Leg Plaster Cast (POT-CAST) trials were performed to compare LMHW and placebo on the basis of their effectiveness in the prevention of symptomatic VTE.

In both the POT-KAST and POT-CAST trials, no significant difference was observed in the frequency of symptomatic VTE between the groups. In both trials, no significant difference was observed in the frequency of major bleeding events between the groups. These results are strengthened by the multi-center, placebo-controlled design of the studies; however, the non-blinded group assignments cannot be excluded as a limitation.

Click to read the study, published today in NEJM

Relevant Reading: Incidence and risk factor analysis of symptomatic venous thromboembolism after knee arthroscopy

RELATED REPORTS

#VisualAbstract: New-onset atrial fibrillation following hospitalization for pneumonia associated with increased thromboembolic risk

ANNEXA-A and ANNEXA-R trials: Andaxanet Alfa for Reversal of Apixaban and Rivaroxaban [Classics Series]

RE-VERSE AD Trial: Idarucizumab for the Reversal of Anticoagulation by Dabigatran [Classics Series]

In-Depth [randomized controlled trial]: This study reports the findings of two parallel, multicenter, open-label, randomized, placebo-controlled trials. The primary outcomes for this study included the overall incidences of symptomatic VTEs and major bleeding within 3 months after the procedure. In the POT-KAST trial (n = 1451), VTE occurred in 5 of the 731 patients (0.7%) of patients who received LMHW and in 3 of the 720 patients (0.4%) who received placebo (RR 1.6, 95%CI 0.4 to 6.8). Major bleeding occurred in 1 of 731 patients (0.1%) of patients who received LMWH and in 1 of 720 (0.1%) patients who received placebo. In the POT-CAST trial (n = 1435), VTE occurred in 10 of the 719 (1.4%) of patients who received LMWH and in 13 of the 716 patients (1.8%) who received placebo (RR 0.8, 95%CI 0.3 to 1.7). No major bleeding events occurred in either group and the most common adverse event was infection.

Image: CC/Wiki

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: anticoagulationarthroscopy
Previous Post

Similar clinical outcomes in mild/moderate Clostridium difficile infection with metronidazole versus vancomycin

Next Post

Potential therapeutic target discovered for triple negative breast cancer [PreClinical]

RelatedReports

#VisualAbstract: New-onset atrial fibrillation following hospitalization for pneumonia associated with increased thromboembolic risk
StudyGraphics

#VisualAbstract: New-onset atrial fibrillation following hospitalization for pneumonia associated with increased thromboembolic risk

June 28, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Critical, Emergent and Pulmonary Care Classics

ANNEXA-A and ANNEXA-R trials: Andaxanet Alfa for Reversal of Apixaban and Rivaroxaban [Classics Series]

June 21, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Critical, Emergent and Pulmonary Care Classics

RE-VERSE AD Trial: Idarucizumab for the Reversal of Anticoagulation by Dabigatran [Classics Series]

June 20, 2022
Intensive rehabilitation not superior to traditional therapy for arm function after stroke
Cardiology

Increased risk of intracranial hemorrhage with aspirin and unfractionated heparin use for endovascular stroke treatment

March 22, 2022
Next Post
Adjunctive TMP-SMX (Bactrim) associated with higher clinical cure rates for cutaneous abscesses

Potential therapeutic target discovered for triple negative breast cancer [PreClinical]

Bariatric surgery linked to decreased all-cause mortality

New probiotic treatment for obesity and diabetes [PreClinical]

Blood pressure variability associated with cardiovascular disease and mortality

Intensive blood pressure control not linked with mobility/gait speed in elderly adults

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Delta variant of SARS-CoV-2 infection associated with higher changes of severe maternal morbidities
  • Endoscopic sleeve gastroscopy effective for excess weight loss in type 1 and 2 obesity
  • #VisualAbstract: Early time-restricted eating was more effective for weight loss than eating over 12-hour window
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.